Axsome Therapeutics (NASDAQ:AXSM) Given New $220.00 Price Target at Robert W. Baird

Posted by Stanley Muller on Nov 3rd, 2026

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its target price decreased by research analysts at Robert W. Baird from $246.00 to $220.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird‘s price target suggests a potential upside of 61.75% from the company’s previous close.

A number of other research firms have also recently commented on AXSM. Morgan Stanley decreased their price target on Axsome Therapeutics from $251.00 to $247.00 and set an “equal weight” rating on the stock in a report on Friday, September 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Axsome Therapeutics in a research note on Thursday, October 15th. Piper Sandler dropped their price objective on Axsome Therapeutics from $258.00 to $238.00 and set an “overweight” rating for the company in a research note on Monday, October 26th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Axsome Therapeutics in a research report on Wednesday, October 14th. Finally, Zacks Research raised Axsome Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $272.26.

Check Out Our Latest Stock Report on Axsome Therapeutics

Axsome Therapeutics Stock Performance

Shares of NASDAQ AXSM opened at $136.01 on Tuesday. The firm has a fifty day moving average price of $183.33 and a 200-day moving average price of $198.74. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.43 and a quick ratio of 1.34. The stock has a market cap of $7.12 billion, a PE ratio of -36.27 and a beta of 0.86. Axsome Therapeutics has a 1 year low of $123.00 and a 1 year high of $260.19.

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) last announced its quarterly earnings data on Monday, November 2nd. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.38. Axsome Therapeutics had a negative net margin of 24.68% and a negative return on equity of 265.55%. The firm had revenue of $259.69 million for the quarter, compared to the consensus estimate of $249.19 million. During the same period last year, the firm earned ($0.94) EPS. The company’s revenue was up 51.9% on a year-over-year basis. Equities analysts anticipate that Axsome Therapeutics will post -3.04 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 10,000 shares of the stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $208.65, for a total transaction of $2,086,500.00. Following the completion of the transaction, the chief operating officer owned 10,000 shares of the company’s stock, valued at $2,086,500. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Herriot Tabuteau sold 4,660 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $213.95, for a total transaction of $997,007.00. Following the transaction, the chief executive officer directly owned 7,229 shares of the company’s stock, valued at $1,546,644.55. This trade represents a 39.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 59,664 shares of company stock worth $12,624,805. 20.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Axsome Therapeutics

Several large investors have recently made changes to their positions in AXSM. Privium Fund Management B.V. boosted its stake in Axsome Therapeutics by 7.5% during the third quarter. Privium Fund Management B.V. now owns 42,944 shares of the company’s stock worth $7,918,000 after buying an additional 3,000 shares during the period. Commonwealth Equity Services LLC boosted its stake in shares of Axsome Therapeutics by 64.7% during the 3rd quarter. Commonwealth Equity Services LLC now owns 4,019 shares of the company’s stock worth $741,000 after purchasing an additional 1,579 shares during the period. Factory Mutual Insurance Co. bought a new position in Axsome Therapeutics during the 3rd quarter valued at about $323,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Axsome Therapeutics in the 3rd quarter worth about $494,000. Finally, Profund Advisors LLC raised its position in Axsome Therapeutics by 608.6% in the 3rd quarter. Profund Advisors LLC now owns 7,291 shares of the company’s stock worth $1,344,000 after purchasing an additional 6,262 shares during the period. 81.49% of the stock is owned by institutional investors.

Trending Headlines about Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

Positive Sentiment: Q3 results exceeded expectations: Axsome reported revenue of $259.7 million, up 51.9% year over year and ahead of the approximately $249.2 million consensus estimate. Its loss narrowed to $0.25 per share, versus analyst expectations for a loss of roughly $0.63 per share and a $0.94 loss in the prior-year quarter. Axsome Q3 earnings flash
Positive Sentiment: Broad commercial and pipeline progress: Sales increased across key brands, while management highlighted additional pipeline milestones expected in 2027, supporting the longer-term growth outlook. Axsome Q3 sales and pipeline update
Neutral Sentiment: Mixed earnings quality: Analysts noted that some of the quarter’s sales improvement reflected one-time items and better gross-to-net adjustments rather than fully sustainable prescription-volume growth. Axsome post-earnings analysis
Negative Sentiment: Auvelity launch concerns dominate: The Alzheimer’s-care launch is reportedly progressing more slowly than hoped, with incremental growth coming primarily from depression prescriptions among patients under 65 rather than from the new Alzheimer’s indication. Those concerns have outweighed the Q3 beat and pushed AXSM toward fresh 52-week lows. AXSM Auvelity launch concerns
Negative Sentiment: Analyst price targets were reduced: UBS lowered its target to $239 from $256, while Piper Sandler cut its target to $235 from $238, reflecting more cautious expectations for the launch and near-term growth. UBS lowers Axsome price target

Axsome Therapeutics Company Profile

(Get Free Report)

Axsome Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system (CNS) disorders. Founded in 2012 and headquartered in New York, the company develops medicines for conditions with significant unmet medical needs, including depression, narcolepsy, excessive daytime sleepiness, and other neurological disorders.

Axsome’s commercial products include Auvelity (dextromethorphan and bupropion), an oral treatment approved in the United States for major depressive disorder in adults, and Sunosi (solriamfetol), a therapy for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea.